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A B S T R A C T
Introduction. A single-armed, prospective, multicenter international study evaluated the redesigned Coloplast Titan
One Touch Release (OTR) pump inflatable penile prosthesis. The OTR pump has a unique release valve that permits
deflation of the implant with one squeeze of opposing touch pads.
Aims. To assess the impact of a new penile prosthesis design, the Titan OTR, on patient ease of operation.
Furthermore, to assess patient satisfaction, surgeon acceptance, and the ease with which patients were trained in
device operation in the clinic setting.
Methods. A total of 113 eligible patients from eight centers were recruited from men presenting with erectile
dysfunction without prior prosthetic implantation. The subjects had a mean age of 61 years, and had a number of
comorbidities, including diabetes (31.9%), hypertension (34.5%), and Peyronie’s disease (23.9%). All underwent
implantation of the study device.
Main Outcome Measures. Questionnaires were used to capture patient satisfaction as well as physician feedback on
ease of implantation and patient education. A paired analysis was completed for patient satisfaction at 6 (N = 96) and
12 (N = 90) months.
Results. Overall satisfaction with the device was 90.6% and 90.0% at 6 and 12 months, respectively. The primary end
point, ease of deflation, was seen in 70.8% and 73.3% at these two time points, with the 12-month value statistically
better than historical controls. Physicians overwhelmingly reported straightforward/simple intraoperative product
preparation (97.3%) and equivalent or easier training compared with their previous pump of choice (96.4%). Adverse
events for all subjects (N = 113) included removal of the device in four cases (3.5%) for infection and one case for
chronic pain (0.8%).
Conclusions. The Titan OTR represents an advance in penile prosthetic technology that is well accepted by patients
and physicians. The study design allowed for realistic evaluation of the new technology aimed at enhancing clinical
outcomes. Ohl DA, Brock G, Ralph D, Bogache W, Jones L, Munarriz R, Levine L, and Ritenour C.
Prospective evaluation of patient satisfaction, and surgeon and patient trainer assessment of the Coloplast
Titan One Touch Release three-piece inflatable penile prosthesis. J Sex Med 2012;9:2467–2474.
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Introduction
E rectile dysfunction (ED) is a prevalent condi-tion. The Massachusetts Male Aging Study
estimated that 52% of men aged 40–70 suffered
from some degree of erectile impairment [1]. In a
large survey of men of all ages in the United States,
Laumann et al. found that the incidence of clini-
cally significant ED was 7% in men aged 18–29
and rose to 18% in men aged 50–59, trailing pre-
mature ejaculation, which was the most common
sexual dysfunction seen in the survey [2]. ED has
many causes, including vascular inflow disease,
veno-occlusive dysfunction, neuropathy, and psy-
chogenic issues.
Medical management of ED was vastly
improved with the introduction of the type 5 phos-
phodiesterase inhibitors in 1998 [3]. However,
efficacy rates with these agents only range from
60% to70% at best, and poorer results are seen in
men with diabetic neuropathy and those who have
undergone radical prostatectomy [4]. In many
men, other treatments, including intraurethral
alprostadil, penile injection therapy, and vacuum
constriction devices, are needed [5]. All these
treatments have advantages and disadvantages.
Furthermore, patient acceptance of those medical
treatments varies widely.
Since the introduction of the inflatable penile
prosthesis (IPP) by Scott et al. in the 1970s [6],
there have been multiple modifications in device
design. Device failures during the early experi-
ence were numerous, and most of the device modi-
fications have been successful efforts directed
toward increasing the mechanical reliability of the
implants [7,8]. The most recent revision of the
device described in the current paper is aimed to
improve the ease of inflation and deflation of the
device.
Aims
The purpose of this study was to determine the
impact of a new penile prosthesis design, the Colo-
plast Titan One Touch Release (OTR; Coloplast
Corporation, Minneapolis, MN, USA), on patient
ease of operation. Furthermore, we sought to
determine patient satisfaction, surgeon accep-
tance, and the ease with which patients were
trained in device operation in the clinic setting.
Methods
A total of 113 eligible patients dispersed over eight
sites underwent implantation of the Titan OTR
IPP from November 2007 to April 2009 in this
prospective, non-randomized, international multi-
center clinical trial. Surgical technique was deter-
mined by the individual surgeon and did not vary
from typical implantation procedures. The study is
prospective in nature, therefore limiting selection
bias via adherence to predefined inclusion and
exclusion criteria. Eligibility criteria included
men at least 18 years of age willing to undergo
implantation of a device to treat ED. Patients with
compromised immune systems, active genitouri-
nary infection, and severe coagulopathies were
among those excluded from the study. Those who
had previous devices implanted for ED were
also excluded. All protocols received institutional
review board approval, and all patients signed
informed consent documents to participate in the
study.
The Titan OTR prosthesis is a three-piece
implant that involves cylinders placed in the corpora
cavernosa of the penis, a pump placed in the scrotum,
and a reservoir placed in the abdominal cavity of the
patient (Figure 1). The entire device has a hydro-
philic coating that rapidly absorbs aqueous solutions
when soaked, and the cylinders and reservoir are
manufactured from silicone and Bioflex (Coloplast
Corporation). The hydraulic OTR pump transfers
fluid between the cylinders and reservoir to allow for
rigidity (inflation) and flaccidity (deflation) of the
penis as appropriate.
The OTR pump has a unique release valve that
permits deflation of the implant with one squeeze
of the opposing touch pads (Figure 2). The size of
the new pump is similar to the previous model.
When the deflate mechanism is activated, the
valve only allows fluid to be transferred from the
Figure 1 Titan One Touch Release three-piece penile
prosthesis
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cylinders to the reservoir. After activation, the
pump is locked in the deflate function, preventing
the need for continuous pressure to allow the flow
toward the reservoir. The OTR pump’s predeces-
sor required constant pressure to be held on the
deflation pads during the deflation process, and
the need for constant pressure was a consistent
complaint of patients. The cost difference between
the OTR pump and its predecessor is approxi-
mately US $200.
Subjects and implanting surgeons completed
baseline questionnaires, and data were collected
by questionnaire at 6 weeks, 3 months, 6 months,
and 12 months after implantation. Data were
compiled, and standard statistical analyses were
performed using SAS version 9.1 or above (SAS
Institute, Cary, NC, USA) or another validated
statistical software package.
Main Outcome Measures
The primary end point of the study was to assess
the satisfaction with ease of deflation of the OTR
pump at 6 months by subject questionnaire.
Retrospective data from three comparator trials
were used to create a weighted average of 64% for
patient satisfaction with pump deflation as a
threshold with which to compare the current study
[9–11]. The primary end point is a binomial
proportion of participants completely or mostly
satisfied with deflation performance, similar to the
criteria for satisfaction reported in the comparator
studies. The end point was constructed as a one-
sided test with a 0.05 alpha level and was analyzed
by comparing the lower bound of the two-sided
90% confidence interval with the performance
goal of 64%.
Assuming a true (expected) rate of satisfaction
of 76%, an alpha level of 0.05 and a one-sided
hypothesis test, this design provides 80% power to
achieve the study objective with a total enrollment
of 92 participants. Allowing for 20% participant
attrition (participant lost to follow-up, participant
death, visits outside the follow-up window), 115
participants needed to be enrolled to reach the
minimum sample size of 92.
Secondary end points included overall satisfac-
tion measures of the patient, implanting surgeon,
and trainer. These were reported with standard
statistical descriptions. For continuous variables,
means, standard deviations, and confidence inter-
vals were reported while categorical variables were
summarized with frequency distributions. Adverse
event data were reported and tabulated from all
sites. Events were reported as procedure or device-
related and classified based on severity.
Results
Patient Population
One hundred twenty-four patients signed consent
forms for the study, but 9 were not implanted
due to medical reasons, withdrawal of consent or
lack of device availability, and 2 were excluded
from analysis after it was determined they did
not actually meet inclusion/exclusion criteria at
baseline. The 113 patients included in the study
were recruited from eight sites, including six in
the United States, one in Canada, and one in the
United Kingdom. Median enrollment per site was
13.5 patients, and no site was permitted to implant
more than 25 patients. At 6 and 12 months there
were 96 and 90 subjects available for analysis,
respectively.
The patient population baseline characteristics
are shown in Table 1. The primary cause of ED
was vascular disease and/or diabetes in more than
half the group. Of note, 34.5% of the patients had
abnormal curvature of the penis, with 23.9%
reported as having evidence of Peyronie’s disease.
Prior ED treatments were given in all the subjects.
These included oral medications (97.3%), penile
injection therapy (63.7%), vacuum device (31%),
intraurethral suppository (19.5%), and testoster-
one administration (5.3%).
Surgical Data
All patients received preoperative and post-
operative antibiotic prophylaxis. Furthermore,
all devices were soaked in antibiotic-containing
Figure 2 One Touch Release pump
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solution prior to implantation. The choice of anti-
biotic solution was based on individual surgeon
preference. The data on individual surgeon pref-
erence were not recorded. A penoscrotal approach
was used in 98% of cases, and operative time
averaged 61.5  22.6 minutes. Average cylinder
length was 15.9  2.0 cm, and reservoir volume
74  11 mL. The average length of rear tip
extenders was 1.9 cm, and in 16 subjects, no rear
tip extenders were utilized. The pump was placed
in the midline in 95% of cases, dartos pouch in
78%, and 65% were surgically secured in place to
prevent migration. Devices were universally filled
with normal saline, and a surgical drain was placed
in 47% of cases.
Surgeon’s Assessment of New Device
Surgeons were asked to answer three questions
regarding the intraoperative experience with the
device. In 97.3% of the cases, the surgeon agreed
that the implant preparation was straightforward.
The surgeons felt that in 89.4% of the cases, the
OTR pump was easier to prepare than their pre-
vious pump of choice. It was determined that the
patient’s scrotum was easily able to accommodate
the pump placement 97.4% of the time. In all of
the above queries, if a positive response was not
given, the response was neutral. In no case was a
negative impression of the device reported.
Trainer’s Assessment of the Device Activation Session
At the 6-week follow-up appointment, patients
were trained in the operation of the device. The
person administering the training session, who
was usually a clinic nurse, was asked to fill out a
questionnaire regarding their impression of the
session. The results are shown in Table 2. As one
can see, the trainers felt that the vast majority of
men found the device somewhat/very/extremely
easy to find the inflation and deflation mechanism
and to operate the device. Ninety-nine point one
percent of subjects reported to the trainer that
they liked the pump. The practitioners felt that
97.2% of subjects found the operation of the
device easy to learn, and in comparison with prior
device training experience, the subject training
with the OTR pump was easier than previous
pumps 99.1% of the time.
Primary End Point Assessment
The primary end point in the study was patient
ease of deflation at 6 months, at which time 70.8%
found the ease of deflation to be satisfactory
or somewhat satisfactory. When compared with
historical controls, as described earlier (64% from
pooled studies), the increase in satisfaction dem-
onstrated a trend for improved satisfaction, but did
not reach statistical significance (lower 95% con-
fidence limit 62.7%, P = 0.082). When analyzing
this end point at 12 months, the satisfaction rate
rose to 73.3%, and this value was statistically
significant to the 64% seen in historical controls
(lower 95% confidence limit 65%, P = 0.033).
It is also important to point out that many
subjects were neutral on ease of deflation at 6 and
12 months. The numbers of men who were neutral
or satisfied with ease of deflation at the two time
points were 83.3% and 80.1%, respectively, with
a minority reporting dissatisfaction (16.7% and
19.9%, respectively).
Table 1 Demographics and baseline characteristics
Characteristic N mean  SD or % (n/N) Range
Age (years) 113 61.0  9.1 (34.5, 81.2)
BMI (kg/m2) 113 29.4  5.0 (18.4, 45.9)
Primary indications (not mutually exclusive)
Vascular disease 113 34.5% (39/113)
Diabetes mellitus 113 31.9% (36/113)
Post-cancer treatment 113 26.5% (30/113)
Pelvic surgery 113 8.8% (10/113)
Neurogenic 113 4.4% (5/113)
Psychological causes 113 4.4% (5/113)
Pelvic trauma 113 4.4% (5/113)
Iatrogenic 113 0.9% (1/113)
Other 113 31.9% (36/113)
Peyronie’s disease 113 23.9% (27/113)
Curvature abnormal 113 34.5% (39/113)
Stretched penile length (cm) 106 11.9  2.5 (6.0, 19.0)
Single sexual partner 113 63.7% (72/113)
SD = standard deviation; BMI = body mass index
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Secondary End Point Assessment
Table 3 shows patient satisfaction with various
aspects of the device at 6 and 12 months. As
one can see, satisfaction rates in all parameters
exceeded 68.9%, with a large proportion of other
responses remaining neutral. The lowest rates
were seen with ease of deflation, as discussed in
the previous section, and length when inflated, a
commonly stated disappointment with all penile
implant patients. At 6 and 12 months, 90.6%/90%
of patients were satisfied with the overall function
of the device. At 12 months, 86.7% stated they
would proceed with the operation again, and
94.5% were either neutral or positive when asked
the question. Eighty-seven point eight percent
would recommend the device to other men with
ED, with 95.6% remaining at least neutral.
Adverse Events
Table 4 shows the total reported adverse events
during the study. The serious adverse events are
shown in Table 5. Overall, there were 41 adverse
events in 30 patients (26.5% of patients experi-
enced at least one adverse event).
Autoinflation was the most common problem
seen at the early follow-up visits (14/113, 12.4%).
Table 2 Clinician/trainer 6-week questionnaire
Characteristic N % (n/N)
It was easy for the subject to find the inflation bulb?
Not at all 108 0.0 (0/108)
A little 108 0.9 (1/108)
Somewhat 108 4.6 (5/108)
Very 108 13.9 (15/108)
Extremely 108 80.6 (87/108)
It was easy for the subject to find the deflation touch pads?
Not at all 108 1.9 (2/108)
A little 108 3.7 (4/108)
Somewhat 108 9.3 (10/108)
Very 108 26.9 (29/108)
Extremely 108 58.3 (63/108)
It was easy for the subject to inflate the device?
Not at all 108 1.9 (2/108)
A little 108 0.9 (1/108)
Somewhat 108 4.6 (5/108)
Very 108 17.6 (19/108)
Extremely 108 75.0 (81/108)
It was easy for the subject to compress the deflation touch pads?
Not at all 108 2.8 (3/108)
A little 108 1.9 (2/108)
Somewhat 108 10.2 (11/108)
Very 108 25.9 (28/108)
Extremely 108 59.3 (64/180)
Subject training with OTR pump was easier than with previous
pump?
Not at all 108 1.9 (2/108)
A little 108 1.9 (2/108)
Somewhat 108 16.7 (18/108)
Very 108 16.7 (18/108)
Extremely 108 63.0 (68/108)
The OTR pump was easy to use at 1st cycling?
Not at all 108 1.9 (2/108)
A little 108 5.6 (6/108)
Somewhat 108 8.3 (9/108)
Very 108 21.3 (23/108)
Extremely 108 63.0 (68/180)
The subject likes the OTR pump?
Not at all 108 0.9 (1/108)
A little 108 3.7 (4/108)
Somewhat 108 13.0 (14/108)
Very 108 20.4 (22/108)
Extremely 108 62.0 (67/108)
How easy was it for the subject to learn?
Not at all 107 2.8 (3/107)
A little 107 8.4 (9/107)
Somewhat 107 7.5 (8/107)
Very 107 29.9 (32/107)
Extremely 107 51.4 (55/107)
OTR = One Touch Release
Table 3 Subject satisfaction at 6 and 12 months
6 months 12 months




96 90.6 (87/96) 90 90 (81/90)
Neither 96 2.1 (2/96) 90 1.1 (1/90)
Soft enough to conceal when deflated
Satisfactory and somewhat
satisfactory
96 76 (73/96) 90 82.2 (74/90)
Neither 96 9.4 (9/96) 90 9.9 (8/90)
Ease of locating the deflation touch pads
Satisfactory and somewhat
satisfactory
96 78.2 (75/96) 89 77.6 (69/89)




95 85.3 (81/95) 88 86.4 (76/88)




96 70.8 (68/96) 90 73.3 (66/90)
Neither 96 12.5 (12/96) 90 6.8 (6/90)
Hardness of erection when inflated
Satisfactory and somewhat
satisfactory
94 91.5 (86/94) 89 93.2 (83/89)




94 86.1 (81/94) 89 79.8 (71/89)




95 61.1 (58/95) 90 68.9 (62/90)
Neither 95 9.5 (9/95) 90 7.8 (7/90)
Would you recommend this penile implant device to men with the
same erectile difficulty that you had?
Yes and probably 96 86.5 (83/96) 90 87.8 (79/90)
Don’t know 96 5.2 (5/96) 90 7.8 (7/90)
If you had the decision to make again, would you undergo this
penile implant procedure again?
Yes and probably 96 83.3 (80/96) 90 86.7 (78/90)
Don’t know 96 9.4 (9/96) 90 7.8 (7/90)
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However, 10 patients reporting autoinflation early
on spontaneously resolved during the course of the
study, leaving the final autoinflation rate of 3.5%.
Many other complications were minor and also
resolved spontaneously.
Infection occurred in four devices and all of these
devices were explanted. Two infections occurred at
a single center and the other two occurred at two
different centers. Therefore, we could not deter-
mine that infection was site-related. The small
number of patients with infection did not allow any
analysis of comorbidities that would put patients at
risk for infection.
One patient with intractable chronic pain also
had his device removed. Seven revision surgeries
were performed, with successful resolution of
the problem. Revisions were performed for device
malfunction (2), discomfort (2), reservoir hernia-
tion (1), and scrotal hematoma (2). The investiga-
tors classified the two device malfunctions as
device-related adverse events and the other revi-
sions as procedure-related.
Discussion
IPPs are well-recognized treatments for ED.
Previous studies have demonstrated high rates of
patient satisfaction [7,10–12], although few studies
have captured prospective data. The current study
provides significant information on satisfaction
captured throughout the first year after surgical
implantation of the Titan OTR IPP. It offers
unique data based on specific collection from
invested parties including surgeons, trainers, part-
ners, and patients.
While oral medications for ED have revolution-
ized the treatment paradigm, these therapies do not
work for all patients. Likewise, other treatments,
while highly effective for some, also do not
provide correction of dysfunction for all [12,13].
Penile prostheses are reliable, effective devices
that provide an alternative for men who wish to
undergo surgical treatment of ED. However,
understanding the issues related to satisfaction
and managing patient expectations are critical
for the implanting surgeon to recognize. Patients
who have IPP surgery but are unable to operate
the device afterward are particularly frustrated.
Therefore, constant assessment and modification
of existing devices is important to provide the best
options for patients.
The Titan OTR IPP was conceived as a safe,
effective device that is easier for patients to use.
While the basic design of the cylinders and res-
ervoir is well established as an effective product,
the IPP pump is the part of the device that
requires the most patient interaction and control.
Creating a pump that allows for easy cylinder
inflation and deflation is an important goal. The
touch pads of the OTR pump allow for a single-
squeeze mechanism that is improved over the
continuous manual pressure required for deflation
of previous devices.
Improved ease of operation of the OTR pump
was verified in a study of practitioners who
perform penile prosthesis training in the clinic
setting. In this study, an in vitro scrotal model with
different pump designs was used to ask these indi-
viduals their opinions of pump designs. The OTR
pump was found to be easier to operate over other
pump designs, and the differences were statistically
significant [14].
Prosthetic surgeons are generally interested in
decreasing operative time. More efficient use
of resources is accomplished by this and some
believe that decreasing operative time may lead
to improved outcomes. Factors that make device
preparation easier can decrease operative time.
In this study, implanting surgeons reported that
device preparation was straightforward/simple
97% of the time. In 89% of the cases, the physician






Auto deflation 2 1.8 (2/113)
Auto inflation 14 12.4 (14/113)
Cylinder extrusion 1 0.9 (1/113)
Cylinder tips asymmetrical 1 0.9 (1/113)
Delayed wound healing 2 1.8 (2/113)
Device malfunction 2 1.8 (2/113)
Discomfort 5 4.4 (5/113)
Fever 1 0.9 (1/113)
Hematoma 4 3.5 (4/113)
Infection 4 3.5 (4/113)
Reservoir herniation 1 0.9 (1/113)
Pain—chronic 1 0.9 (1/113)
Penile edema 1 0.9 (1/113)
SST deformity 2 1.8 (2/113)
Total 41 26.5 (30/113)
SST = supersonic transport







Cylinder extrusion 1 0.9 (1/113)
Device malfunction 2 1.8 (2/113)
Hematoma 2 1.8 (2/113)
Infection 4 3.5 (4/113)
Pain—chronic 1 0.9 (1/113)
Total severe 10 7.1 (8/113)
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stated the pre-implant preparation was easier than
other IPP pumps. These data reflect overall satis-
faction with intraoperative device handling.
Likewise, postoperative training for IPP
patients can require significant amounts of
time. For Titan OTR study patients, training was
completed around 6 weeks after implantation. The
study represents one of the first to capture pro-
spective data from those training the patient. With
this pump design, the trainers reported that the
process was easier than with previous IPP pumps
in 96% of cases. The importance of ease of patient
education for device use cannot be understated,
as this will translate to less time required by
the office staff, fewer remedial training sessions,
and less frustration for patients. Indeed, Shaw
and Garber demonstrated a statistically signifi-
cant decrease in the number of training sessions
required with the OTR pump, as compared with
its predecessor [15].
Perhaps the most important measure of
success after IPP implantation is that of patient
satisfaction with use. Traditionally, IPP patient sat-
isfaction rates have been around 90% [16], and the
current study again shows >90% overall patient
satisfaction at 6 and 12 months. Satisfaction regard-
ing deflation with the OTR device in particular
compares well with previous studies with 70.8%
and 73.3% responding positively to this question at
6 and 12 months, respectively. At 12 months, the
patient satisfaction with ease of deflation was sta-
tistically better than historical controls. One could
argue that this is not clinically significant, because
the difference between the ease of deflation
and historical controls is modest. However, any
improvement in the satisfaction of the patient
undergoing implant surgery is an advance in pros-
thetic surgery.
It is possible that satisfaction rates may be
affected by the type of disease present. For example,
prior studies have suggested a lower rate of ED
treatment satisfaction in men with Peyronie’s
disease. At the time of this writing, analysis by
disease state has not yet been completed but is
planned. Other factors that have recently been
shown to affect postoperative satisfaction include
reasonable preoperative expectations [17] and
favorable female sexual function [18].
The adverse events identified in this study are
well recognized in patients undergoing penile
prosthetic surgery. In particular, early autoinfla-
tion was identified in 12.4%, but most of these
cases resolved spontaneously with no further
intervention needed such that the autoinflation
rate was 3.5% at the end of the study. This is
similar to the rate of 4.3% identified in a previous
study [19].
The number of infections in this study is
higher than typically reported to implant company
databases. Since report forms submitted to the
implant companies are voluntary and incomplete,
it is likely that underreporting of complications to
such databases occurs. This study collected data
prospectively and was complete. Nevertheless, the
infection rate of 3.4% is higher than reported in
recent publications, and may reflect the effects of a
small number of patients presently included. More
investigations are in order to assure that this infec-
tion rate does not represent the true infection rate
of this device. Since the materials are unchanged
from the previous devices, the authors believe that
the high infection rate seen here will not be seen
in future studies. Standardized antibiotic coating
of the hydrophilic surface of the Titan device
may help. Dhabuwala’s group has suggested that
rifampin and gentamicin may be the ideal choice
of antibiotic solution [20].
This study represents one of the few prospective
studies assessing penile implants. There are,
however, several limitations of the trial. Due to
staggered regulatory and Institutional Review
Board (IRB) approvals of the protocol, several
centers started surgical implantations earlier and
entered higher subject numbers into the study. The
comparison used for primary end point assessment
relied on historical data. Furthermore, the com-
parator trials assessed satisfaction data that were
collected at much later time intervals after surgery.
If, for example, there is a progressive improvement
over time in patient acceptance, the 64% cut point
in ease of deflation may be too high when compar-
ing with 6- and 12-month data. Indeed, in the
current study there was an improvement in primary
end point data between the 6- and 12-month marks.
Finally, it is important to recognize that there
was no “head-to-head” comparisons in this trial,
only historical controls from the literature. Ideally,
a head-to-head comparison with two current
devices would be interesting. Furthermore, iden-
tical questionnaires were not used in this and prior
studies, possibly confounding the comparison.
Also, the number of centers utilized in this study
was few, and if extended to more cooperating
centers in future studies, a stronger data set could
be generated in future studies. An ideal compara-
tor study would be a prospective, randomized large
multicenter study comparing two different devices
under the same conditions.
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Conclusions
In this prospective study, the Coloplast Titan
OTR performed well in all measures of patient and
clinician satisfaction. The device was felt by the
implanters to be easier to prepare than the previ-
ous standard pump. The patient trainers found
that it was easier to train patients in the operation
of the device than previous devices, and this may
lead to decreased training time and limitation of
remedial training sessions. Finally, there was high
satisfaction in all aspects of the device and higher
satisfaction rates in the primary end point (ease of
deflation) when compared with pooled historical
controls at 12 months.
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